Brexpiprazole to

Phase 3Small molecule

Otsuka

Brexpiprazole to is one of 83 small molecule programs targeting Major Depressive Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Major Depressive DisorderActive, not recruiting

SchizophreniaActive, not recruiting

Major Depressive DisorderPhase 3

Active, not recruiting

SchizophreniaPhase 1

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Brexpiprazole to

Otsuka

Phase 3

2 2

Celexa

AbbVie

Preclinical

4 3

Ozempic

Novo Nordisk

Preclinical

1 4

Resotran

Takeda

Preclinical

1 5

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 6

Zocor

OOrganon and Co

Preclinical

6 7

Depakote

Ibrance

Lunesta

3 10

Luvox

SSolvay Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schizophrenia2 trials

A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia

Withdrawn· Otsuka logo

Otsuka·Phase 1·NCT05119894

PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia

Completed· Otsuka logo

Otsuka·Phase 1·NCT01854944·12 enrolled

Oral1 trial

Bioequivalence Study of Brexpiprazole Orally Disintegrating Tablets (ODT) 2mg

Completed· Otsuka logo

Otsuka·Phase 1·NCT03902574·21 enrolled

Major Depressive Disorder1 trial

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

Completed· Otsuka logo

Otsuka·Phase 3·NCT02196506·837 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Brexpiprazole to. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Brexpiprazole to compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Brexpiprazole to. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Otsuka company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Otsuka

Brexpiprazole to

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Schizophrenia2 trials

Oral1 trial

Major Depressive Disorder1 trial

References

Drug Info

Quick Facts

Related News